What Auxilium Biotechnologies does

Auxilium Biotechnologies is a clinical-stage biotechnology company developing regenerative medicine solutions centered on microgravity-based 3D bioprinting and implantable medical devices. The company operates two core product lines. The first is NeuroSpan Bridge™, described as the world's first biomimetic peripheral nerve repair device, which uses proprietary microchannel architecture to mimic the fascicular organization of peripheral nerves and align regenerating axons with their intended targets; it is currently in clinical trials under FDA IDE approval, with first patient enrolled in May 2025. The second is the AMP-1 Platform, a proprietary digital light processing (DLP) bioprinter engineered for microgravity environments that has demonstrated production of perfusable blood vessels in under one hour and eight implantable medical devices in two hours aboard the International Space Station.

The company's underlying technology exploits microgravity conditions to fabricate tissue structures and implantable devices with material properties and architectures not achievable under Earth gravity, including perfusable vascular systems and aligned nerve guidance conduits. Auxilium's go-to-market is bifurcated: NeuroSpan Bridge is positioned for enterprise field sales to healthcare providers treating traumatic peripheral nerve injury, while the AMP-1 platform is commercialized via strategic partnerships with commercial space station operators (Starlab Space, Vast) and research institutions (UC San Diego Sanford Stem Cell Institute, LambdaVision, BioOrbit) to deliver in-space biomanufacturing services for life science researchers. The company is privately held, headquartered in the Los Angeles area, founded in 2019, employs 11-50 people, and has raised approximately $7.2 million across disclosed rounds including an active $10 million SEC Form D offering filed in December 2025.

Customer segments are two-fold: peripheral nerve injury patients (primary use case for NeuroSpan Bridge) and life science research institutions seeking microgravity biomanufacturing capabilities (secondary use case for AMP-1 services). The company is pre-revenue, with all current income derived from equity financing and likely NASA-related grant funding following its 2022 NASA selection for a second-generation drug-delivery device proposal. Pricing for both product lines is not publicly disclosed, with commercial pricing contingent on future FDA approval for NeuroSpan Bridge and on service contract terms for AMP-1 biomanufacturing engagements.

Name

Auxilium Biotechnologies

Legal name

Auxilium Biotechnologies Inc.

Website

https://auxiliumbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Auxilium Biotechnologies is a clinical-stage biotechnology company developing the NeuroSpan Bridge peripheral nerve repair device and the AMP-1 microgravity bioprinting platform, serving peripheral nerve injury patients and life science research institutions.

Ownership category

akta.pro rank

Product category

Peripheral Nerve Repair Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

akta.pro secondary industries

Neural & Spinal Cord Regeneration (HLAAAGAI), Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)

Keywords

• Peripheral nerve repair
• Bioprinting medical devices
• Microgravity biomanufacturing
• Regenerative medicine devices
• Tissue engineering implants

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Implantable Medical Devices: Revenue from development and commercialization of implantable medical devices including the NeuroSpan Bridge nerve regeneration device. The company is currently in clinical trials with FDA IDE approval stage, suggesting a path to commercialize these products once regulatory approval is obtained.
2. Space-based Biomanufacturing Services: Revenue from providing orbital 3D bioprinting and biofabrication capabilities aboard commercial space stations for research in regenerative medicine, implantable medical technologies, and tissue engineering. Partnerships with Starlab and Vast position the company to offer microgravity manufacturing services to life science researchers.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Auxilium Biotechnologies develops and commercializes the NeuroSpan Bridge™, a biomimetic peripheral nerve repair device currently in FDA IDE clinical trials. The company also operates the AMP-1 Platform, a proprietary digital light processing 3D bioprinter designed for microgravity environments to fabricate implantable medical devices and perfusable vascular systems aboard the International Space Station and future commercial space stations.

Product overview

Auxilium Biotechnologies is a biotechnology company developing bioprinting solutions and implantable medical devices for regenerative medicine. The company's portfolio consists of two core offerings: NeuroSpan Bridge™, the world's first biomimetic nerve repair device designed for peripheral nerve regeneration currently in clinical trials; and the AMP-1 Platform, a digital light processing 3D bioprinter capable of producing implantable medical devices and perfusable vascular systems in microgravity environments aboard the International Space Station and future commercial space stations.

Differentiator

Problem solved

Functional benefit

Products and services

• NeuroSpan Bridge™ World's first biomimetic nerve repair device that directs nerve regeneration across injury sites by aligning nerve bundles with their intended targets using microchannels that mimic the fascicular architecture of peripheral nerves. Currently in clinical trials for patients with traumatic peripheral nerve injuries.
• AMP-1 Platform Proprietary digital light processing 3D bioprinting platform designed for microgravity environments, supporting in-space biofabrication for regenerative medicine, implantable medical devices, and tissue engineering research. Demonstrated aboard the International Space Station and slated for future commercial space stations.
• Space-based Biomanufacturing Services Microgravity 3D bioprinting and biofabrication services offered to life science researchers and institutions for regenerative medicine, implantable medical device development, tissue engineering, disease modeling, and drug development applications that cannot be replicated under Earth gravity.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Six partnerships are on record, tiered core and minor.

• VastcoreStrategic or Co-development Partner · 24 June 2026Memorandum of understanding signed with Vast to continue and expand biomedical research work currently conducted on the International Space Station after ISS retirement. Auxilium will leverage its 3D bioprinting capabilities for microgravity research aboard Vast's future commercial space station.
• Sanford Stem Cell Institute at UC San DiegominorStrategic or Co-development Partner · 24 June 2026Part of Vast's partner network for microgravity research. Sanford Stem Cell Institute collaborates with Auxilium and other organizations to continue ISS biomedical research after station retirement.
• LambdaVisionminorStrategic or Co-development Partner · 24 June 2026Part of Vast's partner network for microgravity research. LambdaVision has completed nine ISS missions testing artificial retina production and raised $7 million last year.
• BioOrbitminorStrategic or Co-development Partner · 24 June 2026Part of Vast's partner network for microgravity research. BioOrbit collaborates with other organizations including Auxilium to continue biomedical research after ISS retirement.
• Starlab Space LLCcoreStrategic or Co-development Partner · 10 February 2026Partnership to provide orbital 3D bioprinting and biofabrication capabilities aboard Starlab's future commercial space station. Auxilium's AMP-1 bioprinter will support research in regenerative medicine, implantable medical devices, and tissue engineering. The collaboration aims to accelerate translation of experimental biology to manufacturable products in microgravity.
• NASAcoreStrategic or Co-development Partner · 15 April 2022Selected by NASA for a proposal to develop a second-generation drug-delivery medical device to more effectively treat people who have sustained traumatic peripheral nerve injury. Demonstrated technology aboard ISS via NASA-sponsored missions.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Organovo: Organovo is a 3D bioprinting company developing functional human tissues for therapeutic and research applications. Comparable as a peer in 3D bioprinting for regenerative medicine, though Auxilium's microgravity focus and medical device orientation are distinguishing factors.
• Axogen: Axogen is the leading commercial player in peripheral nerve repair, offering nerve grafts (Avance), connectors, and caps. Directly comparable to Auxilium as the primary established company focused on surgical solutions for peripheral nerve injury.

Broad incumbents

• Integra LifeSciences: Integra LifeSciences manufactures a broad portfolio of neurosurgical implants, regenerative technologies, and surgical instruments including nerve repair products. Comparable as a diversified incumbent with overlapping nerve repair and neurosurgical device offerings.
• 3D Systems: 3D Systems is an established 3D printing hardware company with healthcare applications including bioprinting research and surgical planning. Comparable as a broad incumbent with overlapping bioprinting and medical device manufacturing capabilities.
• BICO (CELLINK): BICO owns CELLINK and other bioprinting and lab automation brands providing 3D bioprinters, bioinks, and tissue engineering consumables. Comparable as an established bioprinting hardware and consumables provider serving regenerative medicine researchers.
• Stryker: Stryker is a major medical device company with neurotechnology, spine, and surgical implant portfolios. Comparable as a broad incumbent that could enter or expand in peripheral nerve repair and regenerative medicine.

Emerging players

• Redwire Corporation: Redwire is a space infrastructure company that has flown bioprinting and manufacturing payloads to the ISS and is developing in-space manufacturing capabilities. Comparable as a peer in commercial space-based biomanufacturing.
• Aspect Biosystems: Aspect Biosystems develops microfluidic 3D bioprinting technology for creating functional human tissues with applications in drug discovery and regenerative medicine. Comparable as an emerging bioprinting peer with tissue engineering focus.

Others

• LambdaVision: LambdaVision is a partner of Auxilium using microgravity to produce artificial retinas aboard the ISS. Comparable as an adjacent microgravity biomanufacturing peer and existing partner in Vast's commercial space station research network.
• BioOrbit: BioOrbit is a partner in Vast's microgravity research network focused on space-based pharmaceutical manufacturing. Comparable as an adjacent microgravity biomanufacturing peer and existing ecosystem partner.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Auxilium Biotechnologies